Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COVID-19: Experimental use of tocilizumab (Roactemra) in severe SARS-CoV-2 related pneumonia
2020-001770-30Phase 2Terminated
- Sponsor
- CHU Ambroise Paré
- Start
- Apr 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tocilizumab in coronavirus disease 2019 (COVID-19) and viral pneumonia, sponsored by CHU Ambroise Paré. Primary endpoint: Clinical status at Day 28. Started Apr 2020; status: terminated.
02
Drugs
tocilizumab
03
Conditions
coronavirus disease 2019 (COVID-19)viral pneumonia
Beyond the preview
Go deeper on 2020-001770-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001770-30.